Physician profile
Randelon D Smith
NPI 1790999753
$10,314.17
in general payments reported to CMS, 2019-2025
40 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $460 · 2021: $782 · 2022: $1,027 · 2023: $1,739 · 2024: $2,105 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,326 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,326.19 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,591.44 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,068.91 | 2019-2025 | Xifaxan, Plenvu, Uceris |
| Gilead Sciences, INC. | $1,056.24 | 2019-2025 | |
| Boston Scientific Corporation | $935.66 | 2019-2025 | Spyglass, Overstitch Endoscopic Suturing System, Exalt Model D |
| Genzyme Corporation | $643.22 | 2022-2025 | |
| Olympus America INC. | $474.39 | 2019-2025 | Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Takeda Pharmaceuticals U.S.A., INC. | $367.00 | 2019-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $287.19 | 2021-2024 | Gi Genius |
| Janssen Biotech, INC. | $227.07 | 2023-2025 | Tremfya, Stelara |
| Celgene Corporation | $214.98 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $178.53 | 2024-2025 | Omvoh, Zepbound |
| Allergan, INC. | $172.39 | 2019 | |
| Omega Medical Imaging, LLC | $170.91 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $163.74 | 2022-2025 | Dupixent |
| Pfizer INC. | $151.69 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $150.28 | 2024 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $136.12 | 2019-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $133.98 | 2022-2025 | |
| Qol Medical, LLC | $122.24 | 2020-2025 | Sucraid |
| Medtronic USA, INC. | $118.01 | 2020 | |
| Ardelyx, INC. | $116.16 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $115.81 | 2022-2023 | |
| Conmed Corporation | $105.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.68 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $62.57 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $53.85 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $51.18 | 2023-2025 | |
| Amgen INC. | $50.50 | 2022-2025 | Amjevita, Avsola, Uplizna |
| Aimmune Therapeutics, INC. | $49.86 | 2024-2025 | Zenpep |
| Fresenius Kabi USA, LLC | $46.11 | 2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $38.15 | 2024-2025 | Iqirvo, Bylvay |
| Ucb, INC. | $28.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.73 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $23.48 | 2022 | |
| Redhill Biopharma INC. | $22.87 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.11 | 2019 | |
| Capsovision, INC. | $16.45 | 2024 | Capsocam Plus |
| Novo Nordisk INC | $16.41 | 2025 | Wegovy |
| Celltrion USA INC. | $15.87 | 2025 | Vegzelma |
| Organon LLC | $15.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randelon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.